Chief Scientific Officer, REGENXBIO Inc.
Olivier Danos is the Chief Scientific Officer of REGENXBIO.
He is a pioneer in the field of gene therapy, and has dedicated his career to advancing the use of this technology to develop life-saving therapies for patients. Olivier joined REGENXBIO in 2017 from Biogen where he was a Senior Vice President in charge of Cell and Gene Therapy. Over the past twenty years, he has played leadership roles in cell and gene therapy as Director of the Gene Therapy Consortium of the University College of London, at the Necker Hospital – Enfants Malades in Paris, as Chief Scientific Officer of Genethon and as senior director of research at Somatix Therapy Corporation. He has held senior research positions at the French National Centre for Scientific Research (CNRS) and at the Institut Pasteur in Paris. Olivier is the former President and a founding member of the European Society of Gene and Cell Therapy.
Olivier received a Master’s in Genetics and Molecular Biology at University of Paris Orsay, and his Ph.D. at the Pasteur Institute and University of Paris Diderot.